Spotlight on etanercept in plaque psoriasis and psoriatic arthritis

BioDrugs

Volumn 19, Issue 6, 2005, Pages 401-403

  Goldsmith, David R ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE; PLACEBO;

ARTHROPATHY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG TOLERABILITY; HUMAN; INFECTION; INJECTION SITE REACTION; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RADIOGRAPHY; REVIEW; SCORING SYSTEM; SHORT COURSE THERAPY;

ARTHRITIS, PSORIATIC; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 30344451711     PISSN: 11738804     EISSN: 11738804     Source Type: Journal    
DOI: 10.2165/00063030-200519060-00007     Document Type: Review

References (24)

1. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002 Jan; 146 (1): 118-21
2. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24 (3): 518-23
3. Lebwohl M. Psoriasis. Lancet 2003 Apr 5; 361 (9364): 1197-204
4. Immunex Corporation. Enbrel® (etanercept): package insert (US) [online]. Available from URL: http://www.wyeth.com [Accessed 2004 Oct 18]
5. Sobell JM, Hallas SJ. Systemic therapies for psoriasis: understanding current and newly emerging therapies. Semin Cutan Med Surg 2003 Sep; 22 (3): 187-95
6. Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002; 62 (17): 2493-537
7. Gaspari A, Gottlieb AB, Kang S, et al. Enbrel improves the clinical and pathologic features of psoriasis [abstract no. 172]. J Invest Dermatol 2002 Jul; 119 (1): 236
8. Ritchlin CT, Haas-Smith SA, Shao T, et al. Etanercept lowers the frequency of circulating osteoclast precursors (OCP) and improves bone marrow edema in patients with erosive psoriatic arthritis. Arthritis Rheum 2003 Dec; 48 (12): 3660-1
9. Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000 Feb; 34: 161-4
10. Nestorov I, DeVries T, Zitnik R. Pharmacokinetics of etanercept, a TNF antagonist, in patients with psoriasis treated in two double-blind phase 3 trials [abstract no. P574]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 148.
11. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
12. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003 Dec; 139 (12): 1627-32
13. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 Nov 20; 349 (21): 2014-22
14. Elewski BE, Boh E, Papp K, et al. Efficacy and safety of etanercept in patients with psoriasis: results of a global phase III study [abstract no. P618]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 159.
15. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
16. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000 Jul 29; 356 (9227): 385-90
17. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004 Jul; 50 (7): 2264-72
18. Gottlieb AB, Gordon K, Wang A, et al. Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment response [abstract no. P566]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 146.
19. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
20. Leonardi CL, Elewski B, Camisa C, et al. The efficacy and safety of etanercept in the re-treatment of psoriasis after relapse [abstract no. P568]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 146.
21. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
22. Krueger GG, Woolley JM, Zitnik R. The effects of etanercept therapy on patient reported outcomes for patients with moderate to severe psoriasis [abstract no. P603]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 155.
23. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
24. Wanke LA, Burge D. Etanercept improves health-related quality of life in patients with psoriatic arthritis [abstract no. P531 plus poster]. 60th Annual Meeting of the American Academy of Dermatology; 2002 Feb 22-27; New Orleans, 198